Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
Appl Health Econ Health Policy. 2022 Jul;20(4):573-585. doi: 10.1007/s40258-022-00715-2. Epub 2022 Feb 8.
To derive the population norms for EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Data collected alongside the Chinese SF-6Dv2 valuation study conducted between June and September 2019 were used. SF-6Dv2 and EQ-5D-5L, as well as social-demographic characteristics and self-reported chronic conditions, were collected through face-to-face interviews among a representative sample of the general population stratified by age, gender, education, and area of residence (urban/rural) in China. SF-6Dv2 and EQ-5D-5L responses were converted to utility values using the corresponding Chinese value sets. Utility values for both measures and EQ VAS scores were summarized by age and gender, and then described by different social-demographic characteristics and chronic conditions.
A total of 3397 respondents (51.2% male, age range 18-90 years) were included. 420 (12.4%) and 1726 (50.8%) respondents reported no problems on all SF-6Dv2 and EQ-5D-5L dimensions, respectively. The mean [standard deviation (SD)] utility values were 0.827 (0.143) for SF-6Dv2 and 0.946 (0.096) for EQ-5D-5L. The mean (SD) EQ VAS score was 87.1 (11.5). Respondents who resided in rural areas, were married, and were employed had higher utility values. Respondents with memory-related diseases or stroke had lower utility values than those with other chronic conditions. Utility values decreased with the increase in the number of chronic conditions.
This study reports the first Chinese population norms for the EQ-5D-5L and SF-6Dv2 derived using a representative sample of the Chinese general population. The norms can be used as references for economic evaluations and healthcare decision-making in China.
为中国一般人群推导 EQ-5D-5L 和 SF-6Dv2 的人群规范。
使用 2019 年 6 月至 9 月进行的中国 SF-6Dv2 估值研究中收集的数据。通过在中国按年龄、性别、教育程度和居住地区（城市/农村）分层的一般人群中进行的面对面访谈，收集了 SF-6Dv2 和 EQ-5D-5L 以及社会人口统计学特征和自我报告的慢性疾病。使用相应的中国值集将 SF-6Dv2 和 EQ-5D-5L 的反应转换为效用值。汇总了两种措施的效用值和 EQ VAS 评分，并按年龄和性别进行了描述，然后按不同的社会人口统计学特征和慢性疾病进行了描述。
共纳入 3397 名受访者（51.2%为男性，年龄 18-90 岁）。分别有 420 名（12.4%）和 1726 名（50.8%）受访者在所有 SF-6Dv2 和 EQ-5D-5L 维度上均无问题。SF-6Dv2 的平均[标准差（SD）]效用值为 0.827（0.143），EQ-5D-5L 为 0.946（0.096）。平均（SD）EQ VAS 评分为 87.1（11.5）。居住在农村地区、已婚和就业的受访者具有更高的效用值。患有记忆相关疾病或中风的受访者的效用值低于其他慢性疾病患者。随着慢性疾病数量的增加，效用值降低。
本研究报告了使用中国一般人群的代表性样本推导的 EQ-5D-5L 和 SF-6Dv2 的中国人群规范的首例报告。该规范可作为中国经济评估和医疗保健决策的参考。
